Medtronic (MDT) said Monday its deep brain stimulation system for the treatment of Parkinson's disease symptoms has been approved by the Food and Drug Administration.
The company's BrainSense adaptive deep brain stimulation provides enhanced therapy personalization for symptom control that automatically adjusts, minimizing the need for patients to manually adjust stimulation. It uses a surgically implanted neurostimulator to transmit electrical signals to specific parts of the brain affected by neurological disorders.
The approval also includes Medtronic's BrainSense electrode identifier, which helps reduce patient time spent in clinic to program their deep brain stimulation settings. By using EI, clinicians can conduct an accurate and precise initial programming, 85% faster compared to traditional electrode selection, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.